IOBT - IO Biotech, Inc. Stock Price, Fair Value and News

1.36USD-0.04 (-2.86%)Delayed

Market Summary

USD1.36-0.04

Delayed

-2.86%

IOBT Stock Price

View Fullscreen

IOBT RSI Chart

IOBT Valuation

Market Cap

89.6M

Price/Earnings (Trailing)

-1.01

Price/Sales (Trailing)

13.85

EV/EBITDA

0.32

Price/Free Cashflow

-1.09

IOBT Price/Sales (Trailing)

IOBT Profitability

EBT Margin

-1354.48%

Return on Equity

-76.64%

Return on Assets

-69.05%

Free Cashflow Yield

-91.7%

IOBT Fundamentals

IOBT Revenue

Revenue (TTM)

6.5M

Rev. Growth (Yr)

57.3%

Rev. Growth (Qtr)

-17.03%

IOBT Earnings

Earnings (TTM)

-88.5M

Earnings Growth (Yr)

-14.16%

Earnings Growth (Qtr)

25.69%

Breaking Down IOBT Revenue

Last 7 days

-4.9%

Last 30 days

-9.3%

Last 90 days

-14.5%

Trailing 12 Months

-30.6%

How does IOBT drawdown profile look like?

IOBT Financial Health

Current Ratio

11.24

IOBT Investor Care

Shares Dilution (1Y)

128.63%

Diluted EPS (TTM)

-1.74

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	6.5M	0	0	0
2023	2.4M	3.5M	4.7M	5.9M
2022	0	0	0	1.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of IO Biotech, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 09, 2024	novo holdings a/s	sold	-988,411	1.5003	-658,809	-
Nov 22, 2023	burkavage brian	bought	5,175	1.035	5,000	chief accounting officer
Nov 21, 2023	burkavage brian	bought	4,950	0.99	5,000	chief accounting officer
Aug 09, 2023	elling christian e	acquired	15,012,300	1.9	7,901,230	-
Aug 09, 2023	lundbeckfond invest a/s	acquired	15,012,300	1.9	7,901,230	-
Aug 09, 2023	novo holdings a/s	bought	5,000,000	2.025	2,469,140	-
Aug 09, 2023	vivo capital ix, llc	bought	6,000,000	1.9	3,157,890	-
Aug 09, 2023	zocca mai-britt	acquired	70,370	1.9	37,037	chief executive officer
Aug 09, 2023	sullivan amy	acquired	93,825	1.9	49,382	chief financial officer
Aug 09, 2023	smith devin whittemore	acquired	9,382	1.9	4,938	general counsel

Which funds bought or sold IOBT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	sold off	-100	-4.00	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-14.17	-54,886	218,090	-%
May 15, 2024	MORGAN STANLEY	reduced	-3.7	-488,347	3,801,220	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	unchanged	-	-276,628	3,190,440	-%
May 15, 2024	Logos Global Management LP	unchanged	-	-74,074	854,321	0.07%
May 15, 2024	Samsara BioCapital, LLC	unchanged	-	-546,002	6,297,230	0.97%
May 15, 2024	ARMISTICE CAPITAL, LLC	reduced	-10.4	-634,600	2,982,520	0.04%
May 15, 2024	Stonepine Capital Management, LLC	reduced	-90.63	-2,861,980	270,169	0.21%
May 15, 2024	Novo Holdings A/S	reduced	-11.46	-2,001,800	8,802,690	0.61%
May 15, 2024	MARSHALL WACE, LLP	unchanged	-	-273,684	3,684,210	0.01%

Are Funds Buying or Selling IOBT?

Are funds buying IOBT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own IOBT

No. of Funds

Unveiling IO Biotech, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 14, 2024	novo holdings a/s	10.1%	6,898,584	SC 13G/A
Feb 14, 2024	avoro capital advisors llc	0%	0	SC 13G/A
Feb 13, 2024	bank of america corp /de/	2.8%	1,844,185	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	5.4%	3,641,345	SC 13G/A
Feb 13, 2024	novo holdings a/s	11.1%	7,557,393	SC 13D/A
Feb 13, 2024	hbm healthcare investments (cayman) ltd.	6.0%	3,944,492	SC 13G/A
Dec 18, 2023	samsara biocapital, l.p.	5.5%	3,640,015	SC 13G
Sep 07, 2023	kurma partners	17.18%	12,253,230	SC 13G
Aug 16, 2023	stonepine capital management, llc	5.8%	3,950,616	SC 13G
Aug 15, 2023	hbm healthcare investments (cayman) ltd.	8.19%	5,523,439	SC 13G/A

Recent SEC filings of IO Biotech, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	10-Q	Quarterly Report
May 14, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 14, 2024	SC 13G/A	Major Ownership Report
May 10, 2024	144	Notice of Insider Sale Intent
Apr 26, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Mar 22, 2024	10-K/A	Annual Report

Peers (Alternatives to IO Biotech, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

IO Biotech, Inc. News

Latest updates

IO Biotech, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Revenue	-17.0%	1,617,000	1,949,000	1,708,000	1,196,000	1,028,000	780,500	457,000	158,000	15,000
Operating Expenses	-28.3%	20,197,000	28,183,000	23,484,000	21,852,000	17,924,000	20,388,500	15,865,000	18,161,000	17,010,000
S&GA Expenses	-100.0%	-	6,413,000	5,829,000	5,348,000	6,024,000	5,956,000	5,843,000	5,935,000	6,704,000
R&D Expenses	-34.3%	14,311,000	21,770,000	17,655,000	16,504,000	11,900,000	14,432,500	10,022,000	12,226,000	10,306,000
EBITDA Margin	6.5%	-13.51	-14.46	-16.54	-20.64	-28.59	-49.47	-	-	-
Interest Expenses	-	-	-	-	-	-	-2,000	78,000	102,000	123,000
Income Taxes	13.6%	400,000	352,000	-400,000	500,000	400,000	965,500	115,000	100,000	100,000
Earnings Before Taxes	26.3%	-19,042,000	-25,829,000	-22,118,000	-20,646,000	-16,638,000	-19,083,500	-15,573,000	-18,391,000	-17,138,000
EBT Margin	6.5%	-13.54	-14.49	-16.65	-20.78	-28.75	-49.76	-	-	-
Net Income	25.7%	-19,457,000	-26,182,000	-21,679,000	-21,178,000	-17,044,000	-20,071,000	-15,688,000	-18,495,000	-17,204,000
Net Income Margin	6.6%	-13.68	-14.64	-16.97	-21.37	-29.42	-50.66	-	-	-
Free Cashflow	-8.9%	-24,943,000	-22,907,000	-16,014,000	-18,301,000	-14,838,000	-12,875,000	-13,466,000	-13,118,000	-20,960,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet												(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-15.0%	128	151	173	118	137	152	162	183	202	222	52.00	-
Current Assets	-15.7%	124	147	168	113	132	148	158	179	199	222	52.00	6.00
Cash Equivalents	-17.6%	118	143	166	110	129	143	151	170	188	212	45.00	3.00
Net PPE	-7.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	-	-
Liabilities	-27.7%	13.00	18.00	15.00	13.00	13.00	13.00	9.00	10.00	8.00	10.00	34.00	3.00
Current Liabilities	-29.7%	11.00	16.00	13.00	11.00	10.00	11.00	6.00	9.00	6.00	10.00	34.00	3.00
Shareholder's Equity	-13.3%	115	133	158	105	124	139	153	172	194	212	-	-
Retained Earnings	-7.4%	-283	-263	-237	-216	-194	-177	-157	-141	-123	-106	-84.97	-38.40
Additional Paid-In Capital	0.4%	408	407	405	330	329	327	325	323	321	320	2.00	1.00
Shares Outstanding	0%	66.00	66.00	66.00	29.00	29.00	29.00	29.00	29.00	29.00	29.00	-	-
Float	-	-	-	-	31.00	-	-	-	73.00	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-9.4%	-24,932	-22,795	-15,990	-18,262	-14,690	-12,526	-13,348	-13,011	-20,844	-19,240	-8,171	-9,343	-3,892	-	-
Share Based Compensation	0.6%	1,567	1,558	2,989	1,624	1,888	1,661	2,401	1,358	1,620	1,299	483	5.00	4.00	-	-
Cashflow From Investing	90.2%	-11.00	-112	-24.00	-39.00	-148	-349	-118	-107	-116	-	-	-	-	-	-
Cashflow From Financing	100.0%	-	-10.00	-	-	-	-	-	-	-	187,543	-	-	65,408	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

IOBT Income Statement

2024-03-31

Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses
Research and development	$ 14,311	$ 11,900
General and administrative	5,886	6,024
Total operating expenses	20,197	17,924
Loss from operations	(20,197)	(17,924)
Other income (expense)
Currency exchange (loss) gain, net	(462)	258
Interest income	1,617	1,028
Total other income	1,155	1,286
Loss before income tax expense	(19,042)	(16,638)
Income tax expense	415	406
Net loss	(19,457)	(17,044)
Net loss attributable to common shareholders	$ (19,457)	$ (17,044)
Net loss per common share, basic	$ (0.3)	$ (0.59)
Net loss per common share, diluted	$ (0.3)	$ (0.59)
Weighted-average number of shares used in computing net loss per common share, basic	65,880,914	28,815,267
Weighted-average number of shares used in computing net loss per common share, diluted	65,880,914	28,815,267
Other comprehensive loss
Net loss	$ (19,457)	$ (17,044)
Foreign currency translation	194	517
Total comprehensive loss	$ (19,263)	$ (16,527)

IOBT Balance Sheet

2024-03-31

Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 117,982	$ 143,193
Prepaid expenses and other current assets	6,146	4,062
Total current assets	124,128	147,255
Restricted cash	268	268
Property and equipment, net	788	847
Right of use lease asset	2,092	2,259
Other non-current assets	883	89
Total non-current assets	4,031	3,463
Total assets	128,159	150,718
Current liabilities
Accounts payable	3,840	3,878
Lease liability - current	666	655
Accrued expenses and other current liabilities	6,537	11,184
Total current liabilities	11,043	15,717
Lease liability - noncurrent	1,650	1,839
Total non-current liabilities	1,650	1,839
Total liabilities	12,693	17,556
Commitments and contingencies (Note 9)
Stockholders' equity
Preferred stock, par value of $0.001 per share; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock, par value of $0.001 per share; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 65,880,914 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	66	66
Additional paid-in capital	408,154	406,587
Accumulated deficit	(283,279)	(263,822)
Accumulated other comprehensive loss	(9,475)	(9,669)
Total stockholders' equity	115,466	133,162
Total liabilities and stockholders' equity	$ 128,159	$ 150,718

About IO Biotech, Inc.

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

CEO	Dr. Mai-Britt Zocca Ph.D.
WEBSITE	iobiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	57

IO Biotech, Inc. Frequently Asked Questions

What is the ticker symbol for IO Biotech, Inc.? What does IOBT stand for in stocks?

IOBT is the stock ticker symbol of IO Biotech, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of IO Biotech, Inc. (IOBT)?

As of Fri May 17 2024, market cap of IO Biotech, Inc. is 89.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of IOBT stock?

You can check IOBT's fair value in chart for subscribers.

What is the fair value of IOBT stock?

You can check IOBT's fair value in chart for subscribers. The fair value of IO Biotech, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of IO Biotech, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for IOBT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is IO Biotech, Inc. a good stock to buy?

The fair value guage provides a quick view whether IOBT is over valued or under valued. Whether IO Biotech, Inc. is cheap or expensive depends on the assumptions which impact IO Biotech, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for IOBT.

What is IO Biotech, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, IOBT's PE ratio (Price to Earnings) is -1.01 and Price to Sales (PS) ratio is 13.85. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. IOBT PE ratio will change depending on the future growth rate expectations of investors.